Overview

Study of Dexycu in Treating Intraocular Inflammation

Status:
COMPLETED
Trial end date:
2024-04-09
Target enrollment:
Participant gender:
Summary
This is a phase III, prospective, randomised, double-masked, placebo-controlled, parallel-design, multicenter study of the efficacy, safety and pharmacokinetics of 9% dexamethasone intraocular injection for the treatment of inflammation associated with cataract surgery.
Phase:
PHASE3
Details
Lead Sponsor:
Ocumension Therapeutics (Shanghai) Co., Ltd
Treatments:
Calcium Dobesilate